From: The efficacy of L-carnitine in patients with nonalcoholic steatohepatitis and concomitant obesity
Parameter | Group | T0 of treatment | T1 after the start of treatment | T2 after the start of treatment |
---|---|---|---|---|
TC, mmol/L | 1 | 7.04 ± 0.28 | 5.96 ± 0.14 | 5.17 ± 0.11** |
2 | 6.95 ± 0.24 | 5.50 ± 0.18** | 4.51 ± 0.04**/*** | |
TG, mmol/L | 1 | 3.25 ± 0.06 | 2.73 ± 0.09** | 1.82 ± 0.05** |
2 | 3.26 ± 0.05 | 2.21 ± 0.06 **/*** | 1.43 ± 0.03**/*** | |
LDL, mmol/L | 1 | 4.84 ± 0.03 | 3.75 ± 0.06** | 2.94 ± 0.05*/** |
2 | 4.81 ± 0.03 | 3.07 ± 0.04**/*** | 2.49 ± 0.03**/*** | |
HDL, mmol/L | 1 | 0.98 ± 0.03 (Men: 0.96 ± 0.04; Woman: 0.94 ± 0.03) | 1.14 ± 0.02** (Men: 1.16 ± 0.03; Woman: 1.12 ± 0.03) | 1.31 ± 0.02*/** (Men: 1.33 ± 0.03; Woman: 1.29 ± 0.03) |
2 | 0.97 ± 0.02 (Men: 0.95 ± 0.03; Woman: 0.93 ± 0.04) | 1.26 ± 0.01**/*** (Men: 0.97 ± 0.03; Woman: 0.93 ± 0.03) | 1.42 ± 0.01**/*** (Men: 1.44 ± 0.04; Woman: 1.40 ± 0.03) | |
AI | 1 | 6.3 ± 0.06* | 4.54 ± 0.04*/** | 2.95 ± 0.04*/** |
2 | 6.14 ± 0.08* | 3.5 ± 0.05*/**/*** | 2.18 ± 0.03*/**/*** |